natgillin/translations-raw huggingface dataset:
Insuman Basal must not be used if this cannot be achieved, i. e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the vial.
Insulina Insuman Basal se ne sme uporabiti, če tega ni mogoče doseči – če suspenzija npr. ostane bistra, se v insulinu pojavijo grude, delci ali kosmi ali se lepijo na steno ali dno viale.
As with all insulin preparations, Insuman Basal must not be mixed with solutions containing reducing agents such as thioles and sulphites.
Tako kot velja za vse pripravke insulinov, tudi zdravila Insuman Basal ne smete mešati z raztopinami, ki vsebujejo reducente, npr. tiole ali sulfite.
Insuman Basal may be mixed with all Sanofi-Aventis human insulins, but NOT with those designed specifically for use in insulin pumps.
Insuman Basal se sme mešati z vsemi humanimi insulini, ki jih izdeluje Sanofi- Aventis, NE pa s tistimi, ki so posebej pripravljeni za uporabo v insulinskih črpalkah.
Insuman Basal must also NOT be mixed with insulins of animal origin or with insulin analogues.
Zdravila Insuman Basal prav tako NE smete mešati z insulini živalskega izvora ali insulinskimi analogi.
Date of first authorisation:
Datumprve pridobitve dovoljenja za promet:
Insuman Basal 40 IU/ ml suspension for injection in a vial
Insuman Basal 40 i. e. / ml suspenzija za injiciranje v viali
68 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
Insuman Basal contains 40 IU of insulin per ml suspension.
En mililiter suspenzije Insuman Basal vsebuje 40 i. e. insulina.
69 In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
Pri bolnikih s hudo okvaro jeter se lahko potreba po insulinu zmanjša zaradi zmanjšane zmožnosti za glukoneogenezo in zmanjšane presnove insulina.
70 Intercurrent illness
Sočasne bolezni
Insuman Basal can be used during breastfeeding.
Zdravilo Insuman Rapid je med dojenjem dovoljeno uporabljati.
71 4.7 Effects on ability to drive and use machines
4. 7 Vpliv na sposobnost vožnje in upravljanja s stroji
In many patients, the signs and symptoms of neuroglycopenia are preceded by signs of adrenergic counter- regulation.
69 Pri mnogih bolnikih se pred znaki in simptomi nevroglikopenije pojavijo znaki adrenergične protiregulacije.
72 A marked change in glycaemic control may cause temporary visual impairment, due to temporary alteration in the turgidity and refractive index of the lens.
Izrazita sprememba glikemične urejenosti lahko prehodno poslabša vid zaradi prehodno spremenjenega turgorja in lomnega količnika indeksa leče.
Most minor reactions to insulins at the injection site usually resolve in a few days to a few weeks.
70 Večina manjših reakcij na insuline na mestu injiciranja ponavadi mine v nekaj dneh do nekaj tednih.
73 Pharmacodynamic characteristics
Farmakodinamične značilnosti
74 6.4 Special precautions for storage
6. 4 Posebna navodila za shranjevanje
Immediately before withdrawal from the vial into the injection syringe, the insulin must be re-suspended.
Tik pred izvlekom iz viale v injekcijsko brizgo je treba insulin ponovno suspendirati.
Do not shake the vial vigorously as this may lead to changes in the suspension (giving the vial a frosted appearance; see below) and cause frothing.
72 povzroči spremembe v suspenziji (ji da "zamrznjen" videz, glejte spodaj) in povzroči penjenje.
Insuman Basal 100 IU/ ml suspension for injection in a cartridge
Insuman Basal 100 i. e. / ml suspenzija za injiciranje v vložku
77 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
Insuman Basal in cartridges has been developed for use in the OptiPen series.
Insuman Basal v vložkih je pripravljen za uporabo v injekcijskih peresnikih OptiPen.
78 In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
Pri bolnikih s hudo okvaro jeter se lahko potreba po insulinu zmanjša zaradi zmanjšane zmožnosti za glukoneogenezo in zmanjšane presnove insulina.
79 4.5 Interaction with other medicinal products and other forms of interaction
4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
80 4.8 Undesirable effects
4. 8 Neželeni učinki
In many patients, the signs and symptoms of neuroglycopenia are preceded by signs of adrenergic counter- regulation.
77 Pri mnogih bolnikih se pred znaki in simptomi nevroglikopenije pojavijo znaki adrenergične protiregulacije.
81 Skin and subcutaneous tissue disorders
Bolezni kože in podkožja
Most minor reactions to insulins at the injection site usually resolve in a few days to a few weeks.
78 Večina manjših reakcij na insuline na mestu injiciranja ponavadi mine v nekaj dneh do nekaj tednih.
82 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
83 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
Insulin pen The cartridges are to be used in conjunction with an insulin pen such as OptiPen and other pens suitable for Insuman cartridges and as recommended in the information provided by the device manufacturer.
80 Vložki se uporabljajo skupaj z insulinskim injekcijskim peresnikom kot je OptiPen in drugimi primernimi injekcijskimi peresniki za vložke Insuman in po navodilih izdelovalca injekcijskega peresnika.
Cartridges Before insertion into the pen, Insuman Basal must be kept at room temperature for 1 to 2 hours and then resuspended to check the contents.
Pred vstavitvijo v injekcijski peresnik mora biti Insuman Basal 1 do 2 uri na sobni temperaturi, potem pa ga je treba za preverjanje vsebine ponovno suspendirati.
Insuman Basal must not be used if this cannot be achieved, i. e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the cartridge.
Insulina Insuman Basal se ne sme uporabiti, če tega ni mogoče doseči – če suspenzija npr. ostane bistra, se v insulinu pojavijo grude, delci ali kosmi ali se lepijo na steno ali dno vložka.
EU/ 1/ 97/ 030/ 086 EU/ 1/ 97/ 030/ 035 EU/ 1/ 97/ 030/ 057 EU/ 1/ 97/ 030/ 091 EU/ 1/ 97/ 030/ 096 EU/ 1/ 97/ 030/ 058
81 EU/ 1/ 97/ 030/ 057 EU/ 1/ 97/ 030/ 058 EU/ 1/ 97/ 030/ 086 EU/ 1/ 97/ 030/ 091 EU/ 1/ 97/ 030/ 096
21 February 1997 Date of latest renewal:
21. februar 1997 Datum podaljšanja dovoljenja za promet:
Insuman Basal 100 IU/ ml suspension for injection in a pre-filled pen.
Insuman Basal 100 i. e. / ml suspenzija za injiciranje v napolnjenem injekcijskem peresniku
OptiSet delivers insulin in increments of 2 IU up to a maximum single dose of 40 IU.
Z injekcijskem peresnikom OptiSet je mogoče odmerek nastavljati v stopnjah po 2 i. e. do največjega posamičnega odmerka 40 i. e.
86 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
Before using OptiSet, the Instructions for Use included in the Package Leaflet must be read carefully.
Pred uporabo OptiSeta natančno preberite navodila za ravnanje z Optisetom v navodilu za uporabo.
87 In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
Hypoglycaemia
84 Hipoglikemija
88 Handling of the pen
Ravnanje z injekcijskim peresnikom
A number of substances affect glucose metabolism and may require dose adjustment of human insulin.
85 Na presnovo glukoze vplivajo številna zdravila oz. snovi in potrebna utegne biti prilagoditev odmerka humanega insulina.
89 4.8 Undesirable effects
4. 8 Neželeni učinki
In many patients, the signs and symptoms of neuroglycopenia are preceded by signs of adrenergic counter- regulation.
86 Pri mnogih bolnikih se pred znaki in simptomi nevroglikopenije pojavijo znaki adrenergične protiregulacije.
90 As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption.
Tako kot pri zdravljenju z vsakim insulinom se lahko na mestu injiciranja pojavi lipodistrofija, ki upočasni lokalno absorpcijo insulina.
Most minor reactions to insulins at the injection site usually resolve in a few days to a few weeks.
87 Večina manjših reakcij na insuline na mestu injiciranja ponavadi mine v nekaj dneh do nekaj tednih.
91 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
92 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
3 ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
3 ml suspenzija v vložku (iz brezbarvnega stekla tipa 1), z batom iz brombutilne gume (tipa 1) ter s prirobljeno aluminijsko zaporko z zamaškom iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1).
Before first use, Insuman Basal must be kept at room temperature for 1 to 2 hours and then resuspended to check the contents.
Pred prvo uporabo mora biti Insuman Basal 1 do 2 uri na sobni temperaturi; potem ga je treba za
Insuman Basal must not be used if this cannot be achieved, i. e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the cartridge.
Insulina Insuman Basal se ne sme uporabiti, če tega ni mogoče doseči, tj. suspenzija npr. ostane bistra, se v insulinu pojavijo grude, delci ali kosmi ali se lepijo na steno ali dno vložka.
Handling of the pen The Instructions for Use included in the Package Leaflet must be read carefully before using OptiSet.
90 Ravnanje z injekcijskim peresnikom Pred uporabo OptiSeta natančno preberite navodila za ravnanje z OptiSetom v navodilu za uporabo.
Only use needles that are compatible for use with OptiSet. • Always perform the safety test before each injection. • If a new OptiSet is used the initial safety test must be done with the 8 units preset by the manufacturer. • The dosage selector can only be turned in one direction. • Never turn the dosage selector (change the dose) after injection button has been pulled out.
Uporabljajte le igle, primerne za uporabo z OptiSetom. • Pred vsakim injiciranjem opravite varnostni preizkus. • Če uporabljate nov OptiSet, morate prvi varnostni preizkus narediti z odmerkom 8 enot, ki ga je nastavil že izdelovalec. • Izbirnik odmerka je mogoče vrteti le v eno smer. • Ko je gumb za injiciranje izvlečen, izbirnika odmerka ne smete več obračati (tj. ne smete več spreminjati odmerka). • Ta injekcijski peresnik uporabljajte samo vi.
94 Then the injection button should be pressed all the way in.
Potem je treba gumb za injiciranje pritisniti povsem do konca.
97 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
98 In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
Pri bolnikih s hudo okvaro jeter se lahko potreba po insulinu zmanjša zaradi zmanjšane zmožnosti za glukoneogenezo in zmanjšane presnove insulina.
99 4.5 Interaction with other medicinal products and other forms of interaction
4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
100 Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage.
Hude hipoglikemije lahko povzročijo nevrološke okvare, zlasti če se ponavljajo.
In many patients, the signs and symptoms of neuroglycopenia are preceded by signs of adrenergic counter- regulation.
97 Pri mnogih bolnikih se pred znaki in simptomi nevroglikopenije pojavijo znaki adrenergične protiregulacije.
101 Not known: injection site inflammation, injection site swelling, injection site pain, injection site pruritus, injection site erythema.
Pogosti: reakcije na mestu injiciranja Občasni: urtikarija na mestu injiciranja Ni znano: vnetje na mestu injiciranja, oteklost na mestu injiciranja, bolečina na mestu injiciranja, srbenje na mestu injiciranja, eritem na mestu injiciranja.
Most minor reactions to insulins at the injection site usually resolve in a few days to a few weeks.
98 Večina manjših reakcij na insuline na mestu injiciranja ponavadi mine v nekaj dneh do nekaj tednih.
103 6.6 Special precautions for disposal and other handling
6. 6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom
Insulin pen The cartridges for OptiClik are to be used in conjunction OptiClik only and as recommended in the information provided by the device manufacturer.
100 Vložki za injekcijski peresnik OptiClik se uporabljajo samo skupaj z injekcijskim peresnikom OptiClik in po navodilih izdelovalca injekcijskega peresnika.
Cartridges Before insertion into the pen, Insuman Basal must be kept at room temperature for 1 to 2 hours and then resuspended to check the contents.
Vložki Pred vstavitvijo v injekcijski peresnik mora biti Insuman Basal 1 do 2 uri na sobni temperaturi, potem pa ga je treba za preverjanje vsebine ponovno suspendirati.
Insuman Basal cartridges for Opticlik are not designed to allow any other insulin to be mixed in the cartridge for Opticlik.
Vložki Insuman Basal za injekcijski peresnik OptiClik niso zasnovani tako, da bi dovoljevali mešanje kakšnega drugega insulina v vložku za injekcijski peresnik OptiClik.
EU/ 1/ 97/ 030/ 116 EU/ 1/ 97/ 030/ 117 EU/ 1/ 97/ 030/ 118 EU/ 1/ 97/ 030/ 119 EU/ 1/ 97/ 030/ 120 EU/ 1/ 97/ 030/ 121
EU/ 1/ 97/ 030/ 116 EU/ 1/ 97/ 030/ 117 EU/ 1/ 97/ 030/ 118
106 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
103 Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
107 In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
104 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
108 Handling of the pen
105 Ravnanje z injekcijskim peresnikom
109 4.8 Undesirable effects
4. 8 Neželeni učinki
110 As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption.
Tako kot pri zdravljenju z vsakim insulinom se lahko na mestu injiciranja pojavi lipodistrofija, ki upočasni lokalno absorpcijo insulina.
General disorders and administration site conditions
107 Splošne težave in spremembe na mestu aplikacije
111 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
5.3 Preclinical safety data
108 5. 3 Predklinični podatki o varnosti
112 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
3 ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
3 ml suspenzija v vložku (iz brezbarvnega stekla tipa 1), z batom (iz brombutilne gume (tipa 1)) ter s prirobljeno zaporko (iz aluminija) z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1)).
Injection needles are not included in the pack.
109 Igle niso priložene.
The Instructions for Use included in the Package Leaflet must be read carefully before using SoloStar.
110 Ravnanje z injekcijskim peresnikom Pred uporabo SoloStarja natančno preberite navodila za ravnanje s SoloStarjem v navodilu za uporabo.
114 Step 2.
111 Korak 2.
EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX
112 EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX
Insuman Comb 15 100 IU/ ml suspension for injection in a vial
Insuman Comb 15 100 i. e. / ml suspenzija za injiciranje v viali
Insuman Comb 15 is a biphasic isophane insulin suspension consisting of 15% dissolved insulin and 85% crystalline protamine insulin.
Insuman Comb 15 je dvofazna suspenzija insulina izofana, sestavljena iz 15% raztopljenega insulina in 85% kristalnega protamin- insulina.
117 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
Insuman Comb 15 contains 100 IU of insulin per ml suspension.
En mililiter suspenzije Insuman Comb 15 vsebuje 100 i. e. insulina.
Patients hypersensitive to Insuman Comb 15 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti- allergic treatment.
Bolniki, ki so preobčutljivi za Insuman Comb 15, a tudi nobenega drugega pripravka ne prenašajo bolje, smejo zdravljenje nadaljevati le pod skrbnim zdravniškim nadzorom in – če je potrebno – ob hkratnem antialergijskem zdravljenju.
118 In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism.
Pri bolnikih z okvaro ledvic se lahko potreba po insulinu zaradi zmanjšane presnove insulina zmanjša.
In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
115 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
119 Intercurrent illness
Sočasne bolezni
Insuman Comb 15 can be used during breastfeeding.
Zdravilo Insuman Comb 15 je med dojenjem dovočljeno uporabljati.
120 4.8 Undesirable effects
4. 8 Neželeni učinki
121 Skin and subcutaneous tissue disorders
Bolezni kože in podkožja
Common: injection site reactions Uncommon: injection site urticaria Not known: injection site inflammation, injection site swelling, injection site pain, injection site pruritus, injection site erythema.
118 Ni znano: vnetje na mestu injiciranja, oteklost na mestu injiciranja, bolečina na mestu injiciranja, srbenje na mestu injiciranja, eritem na mestu injiciranja.
Insuman Comb 15 (a biphasic isophane insulin suspension with 15% dissolved insulin) is an insulin with gradual onset and long duration of action.
Insuman Comb 15 (dvofazna suspenzija insulina izofana s 15% raztopljenega insulina) je insulin s postopnim začetkom in dolgim trajanjem delovanja.
122 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
123 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
Immediately before withdrawal from the vial into the injection syringe, the insulin must be re-suspended.
120 Tik pred izvlekom iz viale v injekcijsko brizgo je treba insulin ponovno suspendirati.
Insuman Comb 15 must not be used if this cannot be achieved, i. e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the vial.
Insulina Insuman Comb 15 se ne sme uporabiti, če tega ni mogoče doseči – če suspenzija npr. ostane bistra, se v insulinu pojavijo grude, delci ali kosmi ali se lepijo na steno ali dno viale.
As with all insulin preparations, Insuman Comb 15 must not be mixed with solutions containing reducing agents such as thioles and sulphites.
Tako kot velja za vse pripravke insulinov, tudi zdravila Insuman Comb 15 ne smete mešati z raztopinami, ki vsebujejo reducente, npr. tiole ali sulfite.
Insuman Comb 15 may be mixed with all Sanofi-Aventis human insulins, but NOT with those designed specifically for use in insulin pumps.
Insuman Comb 15 se sme mešati z vsemi humanimi insulini, ki jih izdeluje Sanofi- Aventis, NE pa s tistimi, ki so posebej pripravljeni za uporabo v insulinskih črpalkah.
Insuman Comb 15 must also NOT be mixed with insulins of animal origin or with insulin analogues.
Zdravila Insuman Comb 15 prav tako NE smete mešati z insulini živalskega izvora ali insulinskimi analogi.
Insuman Comb 15 40 IU/ ml suspension for injection in a vial
Insuman Comb 15 40 i. e. / ml suspenzija za injiciranje v viali
126 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
Insuman Comb 15 contains 40 IU of insulin per ml suspension.
En mililiter suspenzije Insuman Comb 15 vsebuje 40 i. e. insulina.
127 In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism.
Pri bolnikih z okvaro ledvic se lahko potreba po insulinu zaradi zmanjšane presnove insulina zmanjša.
In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
123 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
128 Intercurrent illness
Sočasne bolezni
Insuman Comb 15 can be used during breastfeeding.
Zdravilo Insuman Comb 15 je med dojenjem dovoljeno uporabljati.
129 4.8 Undesirable effects
4. 8 Neželeni učinki
130 Skin and subcutaneous tissue disorders
Bolezni kože in podkožja
Common: injection site reactions Uncommon: injection site urticaria Not known: injection site inflammation, injection site swelling, injection site pain, injection site pruritus, injection site erythema.
126 Ni znano: vnetje na mestu injiciranja, oteklost na mestu injiciranja, bolečina na mestu injiciranja, srbenje na mestu injiciranja, eritem na mestu injiciranja.
131 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
132 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
Immediately before withdrawal from the vial into the injection syringe, the insulin must be re-suspended.
128 Tik pred izvlekom iz viale v injekcijsko brizgo je treba insulin ponovno suspendirati.
21 February 1997 Date of latest renewal:
21. februar 1997 Datum zadnje podaljšanja dovoljenja za promet:
Insuman Comb 15 100 IU/ ml suspension for injection in a cartridge
Insuman Comb 15 100 i. e. / ml suspenzija za injiciranje v vložku
135 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
Insuman Comb 15 in cartridges has been developed for use in the OptiPen series.
Insuman Comb 15 v vložkih je pripravljen za uporabo v injekcijskih peresnikih OptiPen.